Brexit Relief For Ireland In New Joint Labeling Plans
Executive Summary
The EU has clarified that after Brexit it will be possible for companies to continue marketing medicinal products with multi-country packs that include the UK market. As most medicines on the Irish and the UK markets share the same labeling, there have been concerns over possible drug shortages if companies choose not to cater to the Irish market alone.